AU2018246214B2 - Niraparib compositions - Google Patents

Niraparib compositions Download PDF

Info

Publication number
AU2018246214B2
AU2018246214B2 AU2018246214A AU2018246214A AU2018246214B2 AU 2018246214 B2 AU2018246214 B2 AU 2018246214B2 AU 2018246214 A AU2018246214 A AU 2018246214A AU 2018246214 A AU2018246214 A AU 2018246214A AU 2018246214 B2 AU2018246214 B2 AU 2018246214B2
Authority
AU
Australia
Prior art keywords
composition
indazole
piperidin
phenyl
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018246214A
Other languages
English (en)
Other versions
AU2018246214A1 (en
Inventor
John Chaber
Jennifer R. Foley
Arlene E. Mckeown
George Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Tesaro Inc
Original Assignee
Merck Sharp and Dohme LLC
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63676949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018246214(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC, Tesaro Inc filed Critical Merck Sharp and Dohme LLC
Publication of AU2018246214A1 publication Critical patent/AU2018246214A1/en
Application granted granted Critical
Publication of AU2018246214B2 publication Critical patent/AU2018246214B2/en
Priority to AU2021245223A priority Critical patent/AU2021245223A1/en
Assigned to MERCK SHARP AND DOHME CORP., TESARO, INC. reassignment MERCK SHARP AND DOHME CORP. Amend patent request/document other than specification (104) Assignors: TESARO, INC.
Assigned to TESARO, INC., MERCK SHARP & DOHME LLC reassignment TESARO, INC. Request to Amend Deed and Register Assignors: MERCK SHARP AND DOHME CORP., TESARO, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
AU2018246214A 2017-03-27 2018-03-27 Niraparib compositions Active AU2018246214B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021245223A AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021245223A Division AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Publications (2)

Publication Number Publication Date
AU2018246214A1 AU2018246214A1 (en) 2019-11-07
AU2018246214B2 true AU2018246214B2 (en) 2021-07-08

Family

ID=63676949

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018246214A Active AU2018246214B2 (en) 2017-03-27 2018-03-27 Niraparib compositions
AU2021245223A Abandoned AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021245223A Abandoned AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Country Status (14)

Country Link
US (3) US11091459B2 (https=)
EP (1) EP3600314A1 (https=)
JP (1) JP2020512350A (https=)
KR (1) KR20200014736A (https=)
CN (1) CN110944638A (https=)
AU (2) AU2018246214B2 (https=)
BR (1) BR112019020211A2 (https=)
CA (1) CA3058375C (https=)
EA (1) EA201992177A1 (https=)
IL (1) IL269630A (https=)
MX (1) MX2019011496A (https=)
SG (1) SG11201909011PA (https=)
TW (1) TWI761476B (https=)
WO (1) WO2018183354A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
AU2019215450A1 (en) 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
UY39201A (es) 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005818A1 (en) * 2016-06-29 2018-01-04 Tesaro, Inc. Methods of treating ovarian cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2007733B1 (en) 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
ES2572652T3 (es) * 2009-08-26 2016-06-01 Cephalon, Inc. Nuevas formas de un compuesto multicíclico
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
CA2935857C (en) 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
PL3954690T3 (pl) 2015-07-02 2023-08-14 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
SG11202006147SA (en) 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
AU2019215450A1 (en) 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
US20210347758A1 (en) * 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005818A1 (en) * 2016-06-29 2018-01-04 Tesaro, Inc. Methods of treating ovarian cancer

Also Published As

Publication number Publication date
IL269630A (en) 2019-11-28
BR112019020211A2 (pt) 2020-04-22
EP3600314A1 (en) 2020-02-05
US20210403448A1 (en) 2021-12-30
WO2018183354A1 (en) 2018-10-04
AU2021245223A1 (en) 2021-11-04
TW201840315A (zh) 2018-11-16
KR20200014736A (ko) 2020-02-11
MX2019011496A (es) 2020-01-23
US11673877B2 (en) 2023-06-13
CA3058375A1 (en) 2018-10-04
JP2020512350A (ja) 2020-04-23
CA3058375C (en) 2025-05-06
US20230416223A1 (en) 2023-12-28
SG11201909011PA (en) 2019-10-30
EA201992177A1 (ru) 2020-02-25
CN110944638A (zh) 2020-03-31
US11091459B2 (en) 2021-08-17
TWI761476B (zh) 2022-04-21
US20200017462A1 (en) 2020-01-16
AU2018246214A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
AU2018246214B2 (en) Niraparib compositions
US11896717B2 (en) Sustained-release dosage forms of ruxolitinib
US20240082231A1 (en) Niraparib formulations
AU2018329202B2 (en) Methods for making and using endoxifen
KR20100093057A (ko) 리카르바제핀 아세테이트를 포함하는 경구 투여형
US20150335609A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN110662534A (zh) 包含(e)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-n-叔丁基苯甲酰胺的药物组合物和药物剂型，其制备方法、治疗方法及用途
WO2004052342A1 (en) A new oral immediated release dosage form
EP2976067B1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
TW202327588A (zh) 治療神經膠質母細胞瘤之方法
CN116322653A (zh) 包括酞嗪酮衍生物的药物组合物
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
CN108853033A (zh) 一种喹硫平药物制剂

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO WU, GEORGE; CHABER, JOHN; MCKEOWN, ARLENE E. AND FOLEY, JENNIFER R.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD APPLICANT MERCK SHARP AND DOHME CORP.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ U, GEORGE; CHABER, JOHN; MCKEOWN, ARLENE E. AND FOLEY, JENNIFER R.

HB Alteration of name in register

Owner name: MERCK SHARP AND DOHME CORP.

Free format text: FORMER NAME(S): TESARO, INC.

Owner name: TESARO, INC.

Free format text: FORMER NAME(S): TESARO, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: TESARO, INC.

Free format text: FORMER NAME(S): TESARO, INC.; MERCK SHARP AND DOHME CORP.

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): TESARO, INC.; MERCK SHARP AND DOHME CORP.